Allison Dorval is Director at PUMA BIOTECHNOLOGY, INC. (PBYI). They have made 4 open-market trades across 1 company since 2020, most recently 2026-06-12.
CIK 0001625110
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PBYI | SELL · 10b5-1 | 2026-06-12 | 2026-06-15 | $7.20 | $84K | +14.0% | +17.8% | +28.3% |
| PBYI | SELL · 10b5-1 | 2025-06-13 | 2025-06-17 | $3.40 | $39K | +0.9% | -1.2% | +36.5% |
| VERV | SELL | 2025-04-02 | 2025-04-03 | $4.15 | $14K | +34.3% | +39.5% | +203.0% |
| VERV | SELL | 2024-12-02 | 2024-12-03 | $5.64 | $3K | -19.4% | -15.1% | -12.9% |
| PBYI | SELL · 10b5-1 | 2024-06-13 | 2024-06-17 | $3.37 | $37K | +2.5% | +14.8% | -20.8% |
| VERV | SELL | 2023-11-29 | 2023-12-01 | $11.45 | $6K | +13.0% | +18.8% | +44.7% |
| PBYI | SELL · 10b5-1 | 2023-06-13 | 2023-06-15 | $3.45 | $35K | -7.6% | -3.4% | -5.4% |
| VERV | SELL | 2022-11-29 | 2022-12-01 | $22.10 | $12K | +2.7% | -13.5% | -16.8% |
| VYGR | SELL · 10b5-1 | 2021-02-11 | 2021-02-16 | $7.55 | $24K | -21.9% | -28.5% | -37.5% |
| VYGR | SELL · 10b5-1 | 2021-01-12 | 2021-01-14 | $8.62 | $25K | -13.9% | -18.4% | -46.7% |
| VYGR | SELL · 10b5-1 | 2020-01-21 | 2020-01-29 | $13.36 | $42K | +14.9% | -3.4% | +2.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.